Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

NCT02906488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 839

Last updated 2025-08-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage

Conditions

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2025-07-24
Completion
2025-07-24

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02906488 on ClinicalTrials.gov